Technetium (99mTc) medronic acid

Technetium (99mTc) medronic acid
Clinical data
Routes of
administration
intravenous
ATC code
Identifiers
PubChem CID
Chemical and physical data
Formula CH6O6P2 • x99mTc
Molar mass unknown
  (verify)

Technetium (99mTc) medronic acid (MDP) is a pharmaceutical product used in nuclear medicine to localize bone metastases[1] as well as other diseases that can alter the natural turn-over in the bone by bone scintigraphy.[2]

Chemistry

The drug is a complex of medronic acid, the simplest bisphosphonate, with technetium-99m (99mTc), a radionuclide that emits gamma rays. The exact structure of the complex is not known.[2][3]

Manufacture

99mTc-MDP must be prepared in a radiopharmacy. It is usually supplied as a "cold kit" to which radioactive 99mTc from a generator is added. Kit composition may vary between suppliers, but contents typically includes medronic acid, stannous chloride dihydrate and sometimes ascorbic acid.[4] Pertechnetate, eluted from the generator is added to the kit vial, which is swirled and left to stand. The labelling efficiency, an indication of how much 99mTc remains in pertechnetate form rather than bound to the MDP, can be measured using chromatography.[5][6][7][8]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.